-
Je něco špatně v tomto záznamu ?
Stratification of lymph node metastases as macrometastases, micrometastases, or isolated tumor cells has no clinical implication in patients with cervical cancer: Subgroup analysis of the SCCAN project
L. Dostálek, K. Benešová, J. Klát, SH. Kim, H. Falconer, J. Kostun, R. Dos Reis, I. Zapardiel, F. Landoni, DI. Ortiz, LRCW. van Lonkhuijzen, A. Lopez, D. Odetto, M. Borčinová, J. Jarkovsky, S. Salehi, K. Němejcová, S. Bajsová, KJ. Park, V....
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články
- MeSH
- biopsie sentinelové lymfatické uzliny MeSH
- lidé MeSH
- lymfatické metastázy patologie MeSH
- lymfatické uzliny patologie MeSH
- mikrometastázy patologie MeSH
- nádory děložního čípku * chirurgie patologie MeSH
- nádory prsu * patologie MeSH
- sentinelová uzlina * patologie MeSH
- staging nádorů MeSH
- Check Tag
- lidé MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
BACKGROUND: In cervical cancer, presence of lymph-node macrometastases (MAC) is a major prognostic factor and an indication for adjuvant treatment. However, since clinical impact of micrometastases (MIC) and isolated tumor-cells (ITC) remains controversial, we sought to identify a cut-off value for the metastasis size not associated with negative prognosis. METHODS: We analyzed data from 967 cervical cancer patients (T1a1L1-T2b) registered in the SCCAN (Surveillance in Cervical CANcer) database, who underwent primary surgical treatment, including sentinel lymph-node (SLN) biopsy with pathological ultrastaging. The size of SLN metastasis was considered a continuous variable and multiple testing was performed for cut-off values of 0.01-1.0 mm. Disease-free survival (DFS) was compared between N0 and subgroups of N1 patients defined by cut-off ranges. RESULTS: LN metastases were found in 172 (18%) patients, classified as MAC, MIC, and ITC in 79, 54, and 39 patients, respectively. DFS was shorter in patients with MAC (HR 2.20, P = 0.003) and MIC (HR 2.87, P < 0.001), while not differing between MAC/MIC (P = 0.484). DFS in the ITC subgroup was neither different from N0 (P = 0.127) nor from MIC/MAC subgroups (P = 0.449). Cut-off analysis revealed significantly shorter DFS compared to N0 in all subgroups with metastases ≥0.4 mm (HR 2.311, P = 0.04). The significance of metastases <0.4 mm could not be assessed due to limited statistical power (<80%). We did not identify any cut-off for the size of metastasis with significantly better prognosis than the rest of N1 group. CONCLUSIONS: In cervical cancer patients, the presence of LN metastases ≥0.4 mm was associated with a significant negative impact on DFS and no cut-off value for the size of metastasis with better prognosis than N1 was found. Traditional metastasis stratification based on size has no clinical implication.
Department of Gynecological Surgery National Institute of Neoplastic Diseases Lima Peru
Department of Surgery Memorial Sloan Kettering Cancer Center New York USA
Gynecologic Oncology Unit La Paz University Hospital IdiPAZ Madrid Spain
Gynecology Oncology Center National Institute of Cancerology Mexico Ciudad De Mexico Mexico
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22032009
- 003
- CZ-PrNML
- 005
- 20230131150645.0
- 007
- ta
- 008
- 230120s2023 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.ygyno.2022.11.017 $2 doi
- 035 __
- $a (PubMed)36442426
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Dostálek, Lukáš $u Department of Obstetrics and Gynecology, General Teaching Hospital and The First Faculty of Medicine of Charles University in Prague, Prague, Czech Republic
- 245 10
- $a Stratification of lymph node metastases as macrometastases, micrometastases, or isolated tumor cells has no clinical implication in patients with cervical cancer: Subgroup analysis of the SCCAN project / $c L. Dostálek, K. Benešová, J. Klát, SH. Kim, H. Falconer, J. Kostun, R. Dos Reis, I. Zapardiel, F. Landoni, DI. Ortiz, LRCW. van Lonkhuijzen, A. Lopez, D. Odetto, M. Borčinová, J. Jarkovsky, S. Salehi, K. Němejcová, S. Bajsová, KJ. Park, V. Javůrková, NR. Abu-Rustum, P. Dundr, D. Cibula
- 520 9_
- $a BACKGROUND: In cervical cancer, presence of lymph-node macrometastases (MAC) is a major prognostic factor and an indication for adjuvant treatment. However, since clinical impact of micrometastases (MIC) and isolated tumor-cells (ITC) remains controversial, we sought to identify a cut-off value for the metastasis size not associated with negative prognosis. METHODS: We analyzed data from 967 cervical cancer patients (T1a1L1-T2b) registered in the SCCAN (Surveillance in Cervical CANcer) database, who underwent primary surgical treatment, including sentinel lymph-node (SLN) biopsy with pathological ultrastaging. The size of SLN metastasis was considered a continuous variable and multiple testing was performed for cut-off values of 0.01-1.0 mm. Disease-free survival (DFS) was compared between N0 and subgroups of N1 patients defined by cut-off ranges. RESULTS: LN metastases were found in 172 (18%) patients, classified as MAC, MIC, and ITC in 79, 54, and 39 patients, respectively. DFS was shorter in patients with MAC (HR 2.20, P = 0.003) and MIC (HR 2.87, P < 0.001), while not differing between MAC/MIC (P = 0.484). DFS in the ITC subgroup was neither different from N0 (P = 0.127) nor from MIC/MAC subgroups (P = 0.449). Cut-off analysis revealed significantly shorter DFS compared to N0 in all subgroups with metastases ≥0.4 mm (HR 2.311, P = 0.04). The significance of metastases <0.4 mm could not be assessed due to limited statistical power (<80%). We did not identify any cut-off for the size of metastasis with significantly better prognosis than the rest of N1 group. CONCLUSIONS: In cervical cancer patients, the presence of LN metastases ≥0.4 mm was associated with a significant negative impact on DFS and no cut-off value for the size of metastasis with better prognosis than N1 was found. Traditional metastasis stratification based on size has no clinical implication.
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a lymfatické metastázy $x patologie $7 D008207
- 650 _2
- $a mikrometastázy $x patologie $7 D061206
- 650 12
- $a nádory děložního čípku $x chirurgie $x patologie $7 D002583
- 650 _2
- $a biopsie sentinelové lymfatické uzliny $7 D021701
- 650 _2
- $a lymfatické uzliny $x patologie $7 D008198
- 650 _2
- $a staging nádorů $7 D009367
- 650 12
- $a nádory prsu $x patologie $7 D001943
- 650 12
- $a sentinelová uzlina $x patologie $7 D000071036
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Benešová, Klára $u Institute of Biostatistics and Analyses, Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic
- 700 1_
- $a Klát, Jaroslav $u Department of Obstetrics and Gynecology, Faculty of Medicine, University Hospital and University of Ostrava, Ostrava, Czech Republic
- 700 1_
- $a Kim, Sarah H $u Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, USA
- 700 1_
- $a Falconer, Henrik $u Department of Pelvic Cancer, Karolinska University Hospital and Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden
- 700 1_
- $a Kostun, Jan $u Department of Gynaecology and Obstetrics, University Hospital Pilsen, Charles University, Prague, Czech Republic
- 700 1_
- $a Dos Reis, Ricardo $u Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, USA
- 700 1_
- $a Zapardiel, Ignacio $u Gynecologic Oncology Unit, La Paz University Hospital - IdiPAZ, Madrid, Spain
- 700 1_
- $a Landoni, Fabio $u Department of Obstetrics and Gynecology, University of Milano-Bicocca, Department of Obstetrics and Gynecology, Gynaecologic Oncology Surgical Unit, ASST-Monza, San Gerardo Hospital, Monza, Italy
- 700 1_
- $a Ortiz, David Isla $u Gynecology Oncology Center, National Institute of Cancerology Mexico, Ciudad De Mexico, Mexico
- 700 1_
- $a van Lonkhuijzen, Luc R C W $u Department of Gynecological Oncology, Amsterdam University Medical Center-Center for Gynecological Oncology Amsterdam, Amsterdam, Netherlands
- 700 1_
- $a Lopez, Aldo $u Department of Gynecological Surgery, National Institute of Neoplastic Diseases, Lima, Peru
- 700 1_
- $a Odetto, Diego $u Department of Gynecologic Oncology, Hospital Italiano de Buenos Aires, Instituto Universitario Hospital Italiano, Buenos Aires, Argentina
- 700 1_
- $a Borčinová, Martina $u Department of Obstetrics and Gynecology, General Teaching Hospital and The First Faculty of Medicine of Charles University in Prague, Prague, Czech Republic
- 700 1_
- $a Jarkovsky, Jiri $u Institute of Biostatistics and Analyses, Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic
- 700 1_
- $a Salehi, Sahar $u Department of Pelvic Cancer, Karolinska University Hospital and Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden
- 700 1_
- $a Němejcová, Kristýna $u Department of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Czech Republic
- 700 1_
- $a Bajsová, Sylva $u Department of Obstetrics and Gynecology, Faculty of Medicine, University Hospital and University of Ostrava, Ostrava, Czech Republic
- 700 1_
- $a Park, Kay J $u Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, USA
- 700 1_
- $a Javůrková, Veronika $u Department of Obstetrics and Gynecology, Faculty of Medicine, University Hospital and University of Ostrava, Ostrava, Czech Republic
- 700 1_
- $a Abu-Rustum, Nadeem R $u Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, USA
- 700 1_
- $a Dundr, Pavel $u Department of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Czech Republic
- 700 1_
- $a Cibula, David $u Department of Obstetrics and Gynecology, General Teaching Hospital and The First Faculty of Medicine of Charles University in Prague, Prague, Czech Republic. Electronic address: dc@davidcibula.cz
- 773 0_
- $w MED00001958 $t Gynecologic oncology $x 1095-6859 $g Roč. 168, č. - (2023), s. 151-156
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/36442426 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20230120 $b ABA008
- 991 __
- $a 20230131150639 $b ABA008
- 999 __
- $a ok $b bmc $g 1891034 $s 1183344
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2023 $b 168 $c - $d 151-156 $e 20221125 $i 1095-6859 $m Gynecologic oncology $n Gynecol Oncol $x MED00001958
- LZP __
- $a Pubmed-20230120
